Want to see AU:BLS full AI Analyst Report?
Top Page
Bioxyne Limited
(Sydney:BLS)
Select Model
Select Model
Rating:78Outperform
Price Target:
AU$0.92
▲(2207.50% Upside)
Action:Reiterated
Date:06/24/26
The score is driven primarily by strong financial performance (rapid revenue growth, improved profitability, low leverage, and materially better cash flow) and supportive bullish technicals (price above key moving averages with positive MACD and healthy RSI). The main offset is valuation, with a P/E of 25 and no dividend yield data to bolster return potential.
Positive Factors
Revenue Growth
Sustained high revenue growth indicates expanding product adoption and market penetration in the medicinal cannabis segment. Over 2–6 months this supports scale advantages, stronger bargaining power with channels, and the ability to invest in capacity or new product commercialization.
Negative Factors
Gross Margin Pressure
A mid-30s gross margin limits the cushion to absorb rising input or compliance costs in cultivation and processing. Without structural margin expansion through productivity or pricing, profitability is more exposed to commodity-like cost swings and competitive discounting.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained high revenue growth indicates expanding product adoption and market penetration in the medicinal cannabis segment. Over 2–6 months this supports scale advantages, stronger bargaining power with channels, and the ability to invest in capacity or new product commercialization.
Read all positive factors
Bioxyne Limited (BLS) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$206.19M
Dividend YieldN/A
Average Volume (3M)4.35M
Price to Earnings (P/E)23.1
Beta (1Y)1.56
Revenue Growth174.51%
EPS Growth265.77%
CountryAU
Employees16
SectorGeneral
Sector StrengthN/A
IndustryPackaged Foods
Share Statistics
EPS (TTM)0.04
Shares Outstanding229,103,590
10 Day Avg. Volume2,483,521
30 Day Avg. Volume4,348,514
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)7.54
Price to Sales (P/S)2.90
P/FCF Ratio22.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bioxyne Limited Business Overview & Revenue Model
Company Description
Headquartered in Sydney, Australia, Bioxyne Limited is a life sciences and health company established in 1998. The firm dedicates itself to the research, development, marketing, and distribution of nutritional supplements and beauty products. Its ...
How the Company Makes Money
Bioxyne Limited makes money primarily by generating revenue from the sale and distribution of medicinal cannabis products and related manufactured goods. Key revenue streams typically include: (1) product sales to pharmacies, clinics, wholesalers,...
Bioxyne Limited Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
82
Very Positive
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Bioxyne Limited Technical Analysis
Positive
0.04
Price Trends
0.84
Positive
0.72
Positive
0.56
Positive
Market Momentum
0.01
Positive
57.78
Neutral
62.79
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:BLS, the sentiment is Positive. The current price of 0.04 is below the 20-day moving average (MA) of 0.94, below the 50-day MA of 0.84, and below the 200-day MA of 0.56, indicating a bullish trend. The MACD of 0.01 indicates Positive momentum. The RSI at 57.78 is Neutral, neither overbought nor oversold. The STOCH value of 62.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:BLS.
Bioxyne Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | AU$206.19M | 23.09 | 56.29% | ― | 174.51% | 265.77% | |
78 Outperform | AU$126.08M | 14.66 | 12.22% | 2.19% | 27.60% | 96.31% | |
56 Neutral | AU$71.53M | 19.29 | 8.70% | ― | 23.29% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
44 Neutral | AU$29.43M | -30.77 | -321.20% | ― | 2.96% | -866.67% | |
44 Neutral | AU$7.33M | -0.01 | 226.76% | ― | -32.83% | 83.37% | |
40 Underperform | AU$12.55M | -2.78 | -41.69% | ― | 53.69% | 45.24% |
* General Sector Average
AU:BLS
Bioxyne Limited
0.97
0.52
115.56%
AU:BUB
Bubs Australia Ltd.
0.08
-0.09
-52.35%
AU:NUC
Nuchev Pty Ltd
0.09
-0.07
-45.16%
AU:HCT
Holista Colltech Limited
0.08
0.01
19.40%
AU:NGS
Nutritional Growth Solutions Ltd.
0.02
0.00
0.00%
AU:CLV
Clover Corporation Limited
0.78
0.28
55.38%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.